Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
- PMID: 18703743
- DOI: 10.1126/science.1158545
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Abstract
Previous attempts have shown the potential of T cells in immunotherapy of cancer. Here, we report on the clinical activity of a bispecific antibody construct called blinatumomab, which has the potential to engage all cytotoxic T cells in patients for lysis of cancer cells. Doses as low as 0.005 milligrams per square meter per day in non-Hodgkin's lymphoma patients led to an elimination of _target cells in blood. Partial and complete tumor regressions were first observed at a dose level of 0.015 milligrams, and all seven patients treated at a dose level of 0.06 milligrams experienced a tumor regression. Blinatumomab also led to clearance of tumor cells from bone marrow and liver. T cell-engaging antibodies appear to have therapeutic potential for the treatment of malignant diseases.
Similar articles
-
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.J Clin Oncol. 2016 Apr 1;34(10):1104-11. doi: 10.1200/JCO.2014.59.1586. Epub 2016 Feb 16. J Clin Oncol. 2016. PMID: 26884582 Clinical Trial.
-
Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab.Exp Cell Res. 2011 May 15;317(9):1255-60. doi: 10.1016/j.yexcr.2011.03.010. Epub 2011 Mar 16. Exp Cell Res. 2011. PMID: 21419116 Review.
-
_targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.J Clin Oncol. 2011 Jun 20;29(18):2493-8. doi: 10.1200/JCO.2010.32.7270. Epub 2011 May 16. J Clin Oncol. 2011. PMID: 21576633 Clinical Trial.
-
Blinatumomab: a historical perspective.Pharmacol Ther. 2012 Dec;136(3):334-42. doi: 10.1016/j.pharmthera.2012.07.013. Epub 2012 Aug 24. Pharmacol Ther. 2012. PMID: 22940266 Review.
-
The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).Best Pract Res Clin Haematol. 2012 Jun;25(2):185-90. doi: 10.1016/j.beha.2012.04.005. Epub 2012 May 18. Best Pract Res Clin Haematol. 2012. PMID: 22687454 Review.
Cited by
-
T-cell engagers: model interrogation as a tool to quantify the interplay of relative affinity and _target expression on trimer formation.Front Pharmacol. 2024 Oct 8;15:1470595. doi: 10.3389/fphar.2024.1470595. eCollection 2024. Front Pharmacol. 2024. PMID: 39439898 Free PMC article.
-
Mechanisms of leukemia resistance to antibody dependent cellular cytotoxicity.Oncoimmunology. 2016 Aug 3;5(9):e1211221. doi: 10.1080/2162402X.2016.1211221. eCollection 2016. Oncoimmunology. 2016. PMID: 27757306 Free PMC article.
-
Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice.Blood Cancer J. 2016 Jun 3;6(6):e430. doi: 10.1038/bcj.2016.38. Blood Cancer J. 2016. PMID: 27258611 Free PMC article.
-
Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia.Clin Pharmacol. 2013 Apr 12;5(Suppl 1):5-11. doi: 10.2147/CPAA.S42689. Print 2013. Clin Pharmacol. 2013. PMID: 23671399 Free PMC article.
-
Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia.Onco _targets Ther. 2015 Jun 24;8:1567-74. doi: 10.2147/OTT.S70524. eCollection 2015. Onco _targets Ther. 2015. PMID: 26170691 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
